Dr. Ishtiaq Rehman MSc PhD
Lecturer in Urological Oncology
Academic Urology Unit
University of Sheffield
Floor K, Royal Hallamshire Hospital
Glossop road
Sheffield
S10 2JF
Telephone: +44 (0)114 271 1798
Fax: +44 (0)114 271 2268
Email: i.rehman@sheffield.ac.uk
Career History
Current Position:
Lecturer (since Jan 2003) in Urological Oncology, Academic Urology Unit, University of Sheffield.
Postdoctoral Fellow at the National Cancer Institute, USA; Molecular Medicine Unit, University of Leeds; Institute for Cancer Studies, University of Sheffield;
Ph.D, Molecular genetic changes in human skin cancer, University of Newcastle upon Tyne;
MSc, Medical Biotechnology, University of Newcastle upon Tyne;
BSc, Biomedical Sciences (Cellular Pathology), University of Bradford.
Research
Our ability to treat prostate cancer rests on a better understanding of the molecular mechanisms underlying tumour development and progression. We are applying Proteomic techniques to identify novel dysregulated proteins involved in the development and progression of human prostate cancer. A recent study aimed at identifying novel biomarkers for the early detection of prostate cancer in voided urine, identified Calgranulin B (S100A9), a member of the calcium binding protein family, which appears to be a promising candidate, since it was detected in the urine of men with cancer but was absent in men without cancer. Studies involving other members of the calcium binding protein family have shown that a number of these are dysregulated in prostate cancer such as S100A2, S100A4, S100A6, S100A11 and are likely to be involved in tumour development and progression. The mechanism underlying the loss of expression of S100A6 was shown for the first time to involve promoter hyper-methylation. Ongoing projects are aimed at (i) Investigating the involvement of other members of the calcium binding protein family in prostate cancer progression, as well as other cancers in collaboration with Dr. S. S Cross (Academic Unit of Pathology), Dr. J.W.F Catto (Academic Urology Unit) and Dr. J.C Deloulme (INSERM, France) (ii) Identifying genes and signalling pathways involved in the metastatic progression of prostate cancer in collaboration with Dr. C. Eaton (Academic Urology Unit). (iii) Investigating the role of S100A11 in prostate cancer progression (iv) Establishing whether gene expression differs in cancer cells found in bone and in the primary tumour in collaboration with Prof. F. C Hamdy (Professor of Urology).
Principal Funding Sources
- National Cancer Research Institute
- MRC
- Sheffield Hospitals Charitable Trust
Peer Reviewed Publications
Caroline Evans, Adam Glen, Colby Eaton, Stephane Larre, James Catto, Freddie Hamdy, Phillip Wright and Ishtiaq Rehman. (2008). Prostate cancer proteomics: The urgent need for clinically validated Biomarkers (Review). Proteomics- Clinical Applications, in press.
Cross S.S, Rehman I, Hamdy F.C, Sethuraman C, Goepel J.R, Malby E. (2008). TMPRSS2 fusions in prostate cancer. Diagnostic Histopathology, in press.
Adam Glen, Chee S. Gan, Freddie C. Hamdy, Colby L. Eaton, Simon S. Cross, James W.F. Catto, Phillip C. Wright and Ishtiaq Rehman. (2008). iTRAQ-facilitated analysis of human prostate cancer cells identifies proteins associated with progression. J Proteome Res, 7(3):897-907.
Rouprêt M, Hupertan V, Catto J.W.F, Yates D.R, Rehman I, Proctor L.M, Phillips J, Meuth M, Cussenot O and Hamdy F.C. (2007). Promoter hypermethylation in circulating blood cells identifies prostate cancer progression. International Journal of Cancer, Oct 24; [Epub ahead of print].
Leiblich A, Cross S.S, Catto J.W.F, Pesce G, Hamdy F.C and Rehman I. (2007). Human Prostate cancer cells express neuroendocrine cell markers PGP 9.5 and Chromogranin A. Prostate, 67(16):1761-9.
Waterman E.A, Cross N.A, Lippitt J.M, Cross S.S, Rehman I, Holen I, Hamdy F.C, Eaton C.L (2007). The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: Implications for association studies with human cancers. Int. J Cancer, Jul 13; [Epub ahead of print].
Catto J.W.F, Yates D.R, Rehman I, Azzouzi A.R, Patterson J, Sibony M, Cussenot O and Hamdy F.C. (2007). A comparative analysis of the behavior of urothelial carcinoma with respect to anatomical location. J Urology, 177(5): 1715-20.
Yates D.R, Rehman I, Abbod M.F, Meuth M, Cross S.S, Linkens D.A, Hamdy F.C and Catto J.W.F. (2007). Promoter hypermethylation identifies progression risk in bladder cancer. Clinical Cancer Res, 13(7):2046-2053.
Rouprêt M, HupertanV, Yates D.R, Catto J.W.F, Rehman I, Ricci S, Lacave R, Cancel-Tassin G, de la Taille A, Rozet f, Cathelineau X, Vallancien G, Hamdy F.C. and Cussenot O. (2007). Molecular diagnosis of localized prostate cancer by quantitative methylation-specific PCR gene patterns in urine cells obtained by prostate massage. Clinical Cancer Res, 13(6):1720-5.
Azzouzi A.R, Catto J.W.F, Rehman I, Feeley K.M, Cussenot O, Meuth M and Hamdy F.C (2007). Clinically localised prostate cancer is microsatellite stable. BJU Int, 99(5): 1031-5.
Rehman I, Goodarzi A, Cross S.S, Leiblich A, Catto J.W.F, Phillips J. and Hamdy F.C. (2007). DNA Methylation and Immunohistochemical Analysis of the S100A4 Calcium Binding Protein in Human Prostate Cancer. The Prostate, 67(4):341-7.
Catto J.W.F, Hartmann A, Stoehr R, Bolderson E, Rehman I, Rosario D.J, Hamdy F.C. and Meuth M. (2006). Multifocal urothelial cancers with the mutator phenotype are of monoclonal origin and require pan-urothelial treatment for tumor clearance. Journal of Urology, 175(6): 2323-30.
Dhawan D, Hamdy F.C, Rehman I, Patterson J, Cross S.S, Feeley K.M, Stephenson Y, Meuth M and Catto J.W.F (2006). Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma. J Pathology, 209(3): 336-43.
Leiblich A, Cross S.S, Catto J.W.F, Phillips J.T, Leung H.Y, Hamdy F.C, Rehman I. (2006). Lactate Dehydrogenase-B is silenced by promoter hypermethylation in human prostate cancer. Oncogene, 25(20): 2953-60.
Yates D, Rehman I, Cross S.S, Meuth M, Hamdy F.C, Catto J.W.F. (2006). Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls. Oncogene, 25(13):1984-8.
Rehman I, Azzouzi A.R, Catto J.W.F, Hamdy F.C. (2005). The use of Proteomics in Urological Research. European Association of Urology (EAU) update series. Review.
Abdel-Fattah R, Glick A, Rehman I, Maiberger P and Hennings H (2006). Methylation of the O6- methylguanine-DNA methyltransferase promoter suppresses expression in mouse skin tumors and varies with the tumor induction protocol. International Journal of Cancer, 11893): 527-31.
Catto J.W.F, Azzouzi A.R, Rehman I, Feeley K.M, Cross S.S, Amira N, Fromont G, Sibony M, Cussenot O, Meuth M and Hamdy F.C. (2005). Promoter methylation is associated with tumor stage, location and subsequent behaviour in transitional cell carcinoma. Journal of Clinical Oncology, 1;23(13):2903-10.
Rehman I, Cross S.S, Catto J.W.F, Leiblich A, Mukherjee A, Azzouzi A.R, Leung H.Y and Hamdy F.C. (2005). Promoter hyper-methylation of calcium binding proteins S100A6 and S100A2 in human prostate cancer. Prostate, 65(4):322-30.
Cross S.S, Hamdy F.C, Deloulme J.C, Rehman I. (2004). Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all over-expressed in common cancers. Histopathology, 35(11):1385-91.
Rehman I, Azzouzi A.R, Cross S.S, Deloulme J.C, Catto J.W.F, Wylde N, Larre S, Champigneuille J. and Hamdy F.C. (2004). Dysregulated expression of S100A11 (Calgizzarin) in prostate cancer and precursor lesions. Human Pathology, 35: 1385-91.
Rehman I, Azzouzi A.R, Catto J.W.F. and Hamdy F.C. (2004). Essential proteomics for urologists. European Urology Today ,( review) December, pp 14-15.
Rehman I, Azzouzi A.R, Catto J.W.F, S. Allen, Cross S.S, Feeley F.M, Meuth M and Hamdy F.C. (2004). Proteomic analysis of voided urine following prostatic massage from prostate cancer patients: A pilot study. Urology, 64 (6):1238-43.
Rehman I, Cross S.S, Azzouzi A.R, Catto J.W, Deloulme J.C, Larre S, Champigneuille J, Fromont G, Cussenot O and Hamdy F.C. (2004). S100A6 (Calcyclin) is a prostate basal cell marker absent in prostate cancer and its precursors. British Journal of Cancer, 91(4): 739-44.
Catto J.W, Azzouzi A.R, Amira N, Rehman I, Feeley K.M, Cross S.S, Fromont G, Sibony M, Hamdy F.C, Cussenot O, Meuth M. (2003). Distinct patterns of microsatellite instability are seen in tumours of the urinary tract. Oncogene, 22 (54): 8699-706.
Murton N.J, French L, Toomes C, Joseph S.S, Rehman I, Hopkins B.L, Inglehearn C.F and Churchill A.J. (2001). A high-density transcript map of the human dominant optic atrophy OPA1 gene locus and evaluation of evidence for a founder haplotype. Cytogenet Cell Genet, 92(1-2): 97-02.
Murton N.J, Rehman I, Black G.C, Inglehearn C.F and Churchill A.J. (2000). A novel deletion (IVS11+3del3) identified in the human PAX-6 gene in a patient with aniridia. Human Mutation, 15(6): 582.
Wu Y.Y, Takata M, Rehman I, Rees J.L. (2000). The temporal and spatial distribution of p21WAF expression in skin appendages. British Journal of Dermatology, 142(4): 694-701.
Rehman I, Lowry D.T, Adams C, Abdel-Fattah R, Holly A, Yuspa S.H. and Hennings H. (2000). Frequent codon 12 Ki-ras mutations in mouse skin tumours initiated by N-methyl-N´-Nitro-N nitrosoguanidine and promoted by mezerein. Molecular Carcinogenesis, 27(4): 298-307.
Mock B, Lowry D, Rehman I, Padlan C, Yuspa S.H and Hennings H. (1998). Multigenic control of skin tumour susceptibility in SENCARA/Pt mice. Carcinogenesis, 19(5): 1109-1115.
Sikkink S, Rehman I and Rees J.L. (1997). Deletion mapping of chromosome 3p and 13q and preliminary analysis of FHIT gene in human non-melanoma skin cancer. Journal of Investigative Dermatology, 109(6): 801-805.
Rehman I, Quinn A.G, Takata M, Taylor A.E and Rees J.L. (1997). Low frequency of allelic loss in skin tumours from immunosuppressed individuals. British Journal of Cancer 76(6): 757-759.
Takata M, Rehman I and Rees J.L. (1997). A trichilemmal carcinoma arising from a proliferating trichilemmal cyst- The loss of the wild-type p53 is a critical event in malignant transformation. Human Pathology, 29(2): 193-5.
Takata M, Rehman I and Rees J.L. (1997). p53 mutation spectrum in Japanese Bowen´s disease suggests a role for mutagens other than ultraviolet light. International Journal of Cancer, 2: 71(3), 370-372.
Rehman I, Takata M, Yih-Ying W and Rees J.L. (1996).Genetic change in actinic keratoses. Oncogene, 12: 2484-2490.
Healy E, Belgaid C.E, Takata M, Vahlquist A, Rehman I, Rigby H and Rees J.L. (1996). Allelotypes of primary cutaneous melanoma and benign melanoytic naevi. Cancer Research, 56(3): 589-93.
Waring A.J, Takata M, Rehman I and Rees J.L. (1996). Loss of heterozygosity analysis of Keratoacanthomas reveals multiple differences from cutaneous squamous cell carcinomas. British Journal of Cancer, 73: 649-653.
Quinn A.G, Healy E, Rehman I and Rees J.L. (1995). Microsatellite Instability in human non melanoma skin cancer. Journal of Investigative Dermatology 104: 309-312.
Healy E, Rehman I and Rees J.L. (1995). Loss of heterozygosity in sporadic primary cutaneous melanoma. Genes Chromosomes Cancer, 12: 152-156.
Rehman I, Quinn A.G, Healy E and Rees J.L. (1994). High frequency of loss of heterozygosity in actinic keratoses a usually benign disease. Lancet, 344: 788-789.
